OncoCyte’s pipeline products are being developed leveraging proprietary algorithms in conjunction with sets of molecular markers that are differentially expressed in specific types of cancer. OncoCyte’s focus on the most common and deadly cancers combined with its experienced leadership team enable it to capitalize on significant commercial opportunities while improving patient outcomes.

pipeline January 2017


The Company’s initial focus will be on confirmatory diagnostics in areas of high unmet need refining the diagnoses associated with:

  • Low Dose CT indeterminate findings for lung cancer
  • Mammogram BIRADS 3-4 (suspicious findings) for breast cancer
  • Cytology indeterminate findings for bladder cancer